menu
    • menu
    [{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NodThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NodThera \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EXS4318","moa":"PKC theta","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NodThera

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed

                            NodThera

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NT-0796

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NodThera's NT-0796 Meets Primary Endpoint in Inflammation Reversal in Obese Subjects

                            Details : NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.

                            Product Name : NT-0796

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 06, 2024

                            Lead Product(s) : NT-0796

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quell Therapeutics

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : eXmoor pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Quell Therapeutics Expands CAR-Treg Manufacturing with eXmoor Pharma

                            Details : Quell & eXmoor are partnering on the process transfer, scale-up, and Phase 1/2 clinical manufacturing of multiple autologous CAR-Treg cell therapies, including QEL-001, for liver transplant patients.

                            Product Name : QEL-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : eXmoor pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quell Therapeutics

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1/2 Trial for Liver Transplant Patients

                            Details : QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.

                            Product Name : QEL-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 06, 2024

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exscientia

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed

                            Exscientia

                            United Kingdom arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXS4318

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

                            Details : EXS4318 is a PKC theta inhibitor which plays a critical role in controlling T cell function and is a key driver of several highly prevalent autoimmune diseases. PKC theta inhibitors have potential in inflammatory and immunologic diseases.

                            Product Name : EXS4318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 02, 2023

                            Lead Product(s) : EXS4318

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth